CBL-514 20mg – Box of 10 Vials
Product batch: EP-250407-CBL514
CBL-514 is an investigational small-molecule lipolysis drug candidate, with reported DYRK1B-inhibitory activity. Each box contains 10 vials, with 20 mg per vial. For qualified laboratory research only.
Testing documentation is pending for this product; no completed Kovera Labs certificate is currently published.
Free shipping on all products.
Research Use Only
For use by qualified professionals in controlled laboratory research. Not for human consumption, therapeutic use or veterinary use.
CBL-514 testing overview
Testing status: pending. Kovera Labs testing for this batch is pending; its certificates will be published on this page and in the COA library when issued.
Product batch: EP-250407-CBL514. For laboratory research use only.
Research evidence
Evidence reviews and laboratory guides relevant to CBL-514 20mg, plus the testing behind each batch.
- CBL-514 mechanism: adipocyte lipolysis evidence synthesis
- CBL-514 clinical trial landscape
- CBL-514 regulatory status in Australia
- CBL-514 comparative evidence map
- CBL-514 research guide
- Synthetic peptides: manufacture, impurities and analytical verification
- Peptides wholesale: supplier qualification and quality
- What are peptides?
- CBL-514 20mg in the COA library
- How we test: purity, endotoxin, heavy metals and sterility
Also tested by Kovera Labs
What is CBL-514?
CBL-514 is an investigational small-molecule lipolysis drug candidate. Its reported mechanism involves DYRK1B inhibition and adipocyte apoptosis, the programmed death of fat cells. [1]
DYRK1B inhibition and adipocyte apoptosis
The 2022 Phase 2a paper describes inhibition of the cell-survival kinase DYRK1B, increased caspase-3 expression and a higher Bax/Bcl-2 ratio in the sponsor's nonclinical studies. These findings describe the proposed mechanism; they are not direct evidence of target engagement in humans. [1]
Conditions and applications under development
- Localised subcutaneous fat reduction: clinical studies assess fat volume and thickness in targeted areas, including the abdomen. [2]
- Dercum's disease (adiposis dolorosa): a published Phase 2a study examined lipoma volume and pain in this disorder of painful fatty growths. These are two names for the same condition. [3]
- Cellulite: The study sponsor has reported Phase 2 results from its CBL-0201EFP programme. [4]
- Obesity and weight management: the sponsor has announced a Phase 2 development programme evaluating CBL-514 alongside a GLP-1/GIP receptor agonist in people with obesity or overweight. This is an investigational application. [5]
Clinical programmes may use different formulations. The study sponsor distinguishes CBL-514D, a formulation with the same active ingredients under development for Dercum's disease. Study results describe the specific formulation and conditions investigated. [5]
Product documentation: Published clinical findings relate to the investigational product studied in those trials. This research material is supplied for laboratory research use only; its batch testing status is shown above.